Zoledronic acid: An evolving role in the treatment of cancer patients with bone disease

Seminars in Oncology

Volumn 28, Issue 2 SUPPL. 6, 2001, Pages 45-47

  Fleisch, Herbert ^a  

^a NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; VITAMIN D; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE METASTASIS; CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034990417     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.24159     Document Type: Review

References (20)

1. Osteolytic tumor bone disease
2. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
3. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
4. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro
5. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
6. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy - A pooled analysis of two randomized, controlled clinical trials
7. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: The role of parathyroid hormone-related peptide
8. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients
9. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
10. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
11. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions. A randomized, placebo-controlled trial
12. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases
13. Phase I, open label, dose-ranging trial of rapid intravenous zoledronic acid, a novel bisphosphonate, in cancer patients with osteolytic bone lesions
14. Zoledronic acid reduces skeletal related events in patient with osteolytic metastases: A double-blind randomized dose-response study
15. Increased urinary excretion of pyridinium crosslinks in cancer patients
16. Biochemical markers of bone turnover in patients with metastatic bone disease
17. High dose pamidronate - Clinical and biochemical effects in metastatic bone disease
18. Markers of bone resorption in patients treated with pamidronate
19. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
20. Bisphosphonates in prostate carcinoma